Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xeomin in Treatment-Naïve Blepharospasm
NCT01896895Phase 3Completed
- Sponsor
- Merz
- Start
- Nov 2013
- Primary completion
- Apr 2016
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 3
01
Overview
A Phase 3 trial of incobotulinumtoxinA in benign essential blepharospasm (BEB), sponsored by Merz. Started Nov 2013; status: completed.
02
Drugs
incobotulinumtoxinA
03
Conditions
benign essential blepharospasm (BEB)
Beyond the preview
Go deeper on NCT01896895.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01896895.